<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345031</url>
  </required_header>
  <id_info>
    <org_study_id>AUT022063</org_study_id>
    <nct_id>NCT02345031</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss</brief_title>
  <acronym>CLARITY-1</acronym>
  <official_title>A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autifony Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autifony Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate that the investigational drug AUT00063 is effective and safe
      in the treatment of age-related hearing loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reduced activity at certain sites in the brain (called &quot;voltage-gated potassium channels&quot;)
      has been linked to hearing problems, like age-related loss of hearing or tinnitus (a
      'ringing' or buzzing noise in the ears).

      AUT00063 is an experimental new medicine that enhances the action of these specific channels
      and so may treat the brain component of these hearing problems.

      The main purpose of this study is to try to demonstrate an improvement in a speech-in-noise
      deficit after 4 weeks of treatment with the study drug versus the placebo (dummy drug which
      does not contain the drug). Subjects will undergo a safety follow-up after the treatment
      period.

      Safety and efficacy will be determined by looking at a number of assessments (physical
      examinations, blood sampling, hearing assessments, questionnaires, etc.).

      The amount of drug in the blood will also be measured. It is expected that around 70 people
      (at least 35 in each arm) with age-related hearing loss may take part in the study. The study
      participants will be recruited at around 13 sites in the USA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hearing Loss After 4 Weeks of Treatment</measure>
    <time_frame>28 days</time_frame>
    <description>To compare the change in hearing using the QuickSIN test (speech in noise performance) from baseline (Day 1 to Day 28) between AUT00063 and placebo. The QuickSIN test measures the level of signal compared to the noise that is required to achieve 50% recognition. The test is administered in a sound booth at 70-dB HL binaurally via insert-ear phones. Three lists are administered to each individual subject and the threshold or 50% signal-to-noise ratio (SNR) is calculated as the mean of the three lists completed. Each list consists of six sentences with five key words to be scored per sentence. The sentences are presented in four-talker babble noise. The sentences are presented at pre-recorded signal-to-noise ratios which decrease in 5-dB steps from 25 (very easy) to 0 (extremely difficult).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of Change From Baseline in Adaptive Test of Temporal Resolution (ATTR) on End-Point Visit Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Final Average GDT Across-Channel at Day 28: Change from Baseline; FAS Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Change From Baseline in Adaptive Test of Temporal Resolution (ATTR) on End-Point Visit Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Final Average GDT Within-Channel at Day 28: Change from Baseline; FAS Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Further Investigate the Safety and Tolerability Profile of Repeat Administration of AUT00063 by Assessing Vital Signs, Physical Examination, Laboratory Exams and ECG</measure>
    <time_frame>42 Days</time_frame>
    <description>To investigate the safety and tolerability of AUT00063 by assessing vital signs, physical examination, laboratory exams and electrocardiography (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of AUT00063, Plasma Levels</measure>
    <time_frame>28 Days</time_frame>
    <description>Exposure of AUT00063 ng/ml, in plasma levels at Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Age-Related Hearing Loss</condition>
  <arm_group>
    <arm_group_label>AUT00063 (600 mg capsules)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(AUT00063 placebo capsules)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules of placebo, to take orally once daily with food for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUT00063</intervention_name>
    <description>600 mg, orally, once a day, for 4 weeks</description>
    <arm_group_label>AUT00063 (600 mg capsules)</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally, once a day, for 4 weeks</description>
    <arm_group_label>(AUT00063 placebo capsules)</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Be between ages 50-89 years old

          -  American-English speaking

          -  Have difficulty hearing speech in a noisy environment

          -  No recent history of middle ear disease

          -  No severe insomnia, major depressive disorders, severe anxiety or post-traumatic
             stress disorder

          -  Not a current or previous user of hearing aids. You are eligible if you were
             noncompliant and stopped wearing a hearing aid device &gt;6 months earlier for
             intermittent use or &gt;3 years if you were a full-time consistent user of hearing aid
             devices

          -  Not be dependent on alcohol or drugs

          -  Have not participated in another research study within 30-days

          -  If female, you must confirm to be non child bearing (post-menopausal for at least
             12-months or surgically sterile)

          -  If male, you must confirm to use a barrier method (condom)

          -  Not be a professional musician

          -  No history of important cardiac, endocrine, pulmonary, neurologic, psychiatric,
             hepatic, renal, hematologic, immunologic, or other major disease deemed clinically
             significant by the study doctor

        While you are in the study, you must:

          -  Follow the instructions you are given

          -  Come to the study centre for all visits with the study doctor or study staff

          -  Answer the telephone at the scheduled date and time for the 2 telephone calls

          -  Tell the study doctor or study staff about any changes in your health or the way you
             feel

          -  Tell the study doctor or study staff if you want to stop being in the study at any
             time

          -  Bring your Diary to each visit

          -  Not eat or drink anything containing Grapefruit beginning 7-days before Baseline visit
             (Visit 3, Day 1) until the end of the study

          -  Use sun screen if you plan to sunbathe

          -  Not use headphones or headsets at high volume

          -  Not use hearing aids or devices at any time during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Frisina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director Global Center for Hearing and Speech Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sacramento ENT</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado ENT and Allergy</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT Associates of South Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS MRA (Miami Research Associates)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research Inc.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Ear, Nose, &amp; Throat Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>August 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2017</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hearing loss</keyword>
  <keyword>speech-in-noise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Presbycusis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AUT00063 (600 mg Capsules)</title>
          <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>(AUT00063 Placebo Capsules)</title>
          <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AUT00063 (600 mg Capsules)</title>
          <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>(AUT00063 Placebo Capsules)</title>
          <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Demographic data are listed from Full Analysis Set, excludes 2 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Demographics data are listed from Full Analysis Set, excludes 2 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Demographic data are listed from Full Analysis Set, excludes 2 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White/Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Demographic data are listed from Full Analysis Set, excludes 2 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic Or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic Or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QuickSIN SNR-50 Score (dB)</title>
          <description>The QuickSIN test measures the level of signal compared to the noise that is required to achieve 50% recognition and were administered in a sound booth at 70-dB HL binaurally. It is reported in decibels (dB).</description>
          <population>QuickSIN data are listed from Full Analysis set, excludes 2 subjects</population>
          <units>decibels (dB)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.00" spread="1.963"/>
                    <measurement group_id="B2" value="7.11" spread="1.991"/>
                    <measurement group_id="B3" value="7.06" spread="1.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hearing Loss After 4 Weeks of Treatment</title>
        <description>To compare the change in hearing using the QuickSIN test (speech in noise performance) from baseline (Day 1 to Day 28) between AUT00063 and placebo. The QuickSIN test measures the level of signal compared to the noise that is required to achieve 50% recognition. The test is administered in a sound booth at 70-dB HL binaurally via insert-ear phones. Three lists are administered to each individual subject and the threshold or 50% signal-to-noise ratio (SNR) is calculated as the mean of the three lists completed. Each list consists of six sentences with five key words to be scored per sentence. The sentences are presented in four-talker babble noise. The sentences are presented at pre-recorded signal-to-noise ratios which decrease in 5-dB steps from 25 (very easy) to 0 (extremely difficult).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>AUT00063 (600 mg Capsules)</title>
            <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>(AUT00063 Placebo Capsules)</title>
            <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hearing Loss After 4 Weeks of Treatment</title>
          <description>To compare the change in hearing using the QuickSIN test (speech in noise performance) from baseline (Day 1 to Day 28) between AUT00063 and placebo. The QuickSIN test measures the level of signal compared to the noise that is required to achieve 50% recognition. The test is administered in a sound booth at 70-dB HL binaurally via insert-ear phones. Three lists are administered to each individual subject and the threshold or 50% signal-to-noise ratio (SNR) is calculated as the mean of the three lists completed. Each list consists of six sentences with five key words to be scored per sentence. The sentences are presented in four-talker babble noise. The sentences are presented at pre-recorded signal-to-noise ratios which decrease in 5-dB steps from 25 (very easy) to 0 (extremely difficult).</description>
          <population>Full Analysis Set</population>
          <units>decibels (dB)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.114" lower_limit="-1.956" upper_limit="-0.272"/>
                    <measurement group_id="O2" value="-1.914" lower_limit="-2.703" upper_limit="-1.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Change From Baseline in Adaptive Test of Temporal Resolution (ATTR) on End-Point Visit Day 28</title>
        <description>Final Average GDT Across-Channel at Day 28: Change from Baseline; FAS Population</description>
        <time_frame>28 days</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>AUT00063 (600 mg Capsules)</title>
            <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>(AUT00063 Placebo Capsules)</title>
            <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline in Adaptive Test of Temporal Resolution (ATTR) on End-Point Visit Day 28</title>
          <description>Final Average GDT Across-Channel at Day 28: Change from Baseline; FAS Population</description>
          <population>FAS Population</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.978" lower_limit="-17.57" upper_limit="11.612"/>
                    <measurement group_id="O2" value="-10.72" lower_limit="-23.90" upper_limit="2.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Change From Baseline in Adaptive Test of Temporal Resolution (ATTR) on End-Point Visit Day 28</title>
        <description>Final Average GDT Within-Channel at Day 28: Change from Baseline; FAS Population</description>
        <time_frame>28 days</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>AUT00063 (600 mg Capsules)</title>
            <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>(AUT00063 Placebo Capsules)</title>
            <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Change From Baseline in Adaptive Test of Temporal Resolution (ATTR) on End-Point Visit Day 28</title>
          <description>Final Average GDT Within-Channel at Day 28: Change from Baseline; FAS Population</description>
          <population>FAS Population</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.452" lower_limit="1.306" upper_limit="7.598"/>
                    <measurement group_id="O2" value="5.526" lower_limit="2.661" upper_limit="8.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Further Investigate the Safety and Tolerability Profile of Repeat Administration of AUT00063 by Assessing Vital Signs, Physical Examination, Laboratory Exams and ECG</title>
        <description>To investigate the safety and tolerability of AUT00063 by assessing vital signs, physical examination, laboratory exams and electrocardiography (ECG)</description>
        <time_frame>42 Days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of AUT00063, Plasma Levels</title>
        <description>Exposure of AUT00063 ng/ml, in plasma levels at Day 28</description>
        <time_frame>28 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AUT00063 (600 mg Capsules)</title>
            <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of AUT00063, Plasma Levels</title>
          <description>Exposure of AUT00063 ng/ml, in plasma levels at Day 28</description>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3470.61" spread="1290.679"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The recording period for Adverse Events is the period starting from the Informed Consent signature until the safety close out visit or subjectâ€™s study participation ends; a total duration of up to 10 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AUT00063 (600 mg Capsules)</title>
          <description>3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
AUT00063: 600 mg, orally, once a day, for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo (AUT00063 Placebo Capsules)</title>
          <description>3 capsules of placebo, to take orally once daily with food for 4 weeks
Placebo: orally, once a day, for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <description>Acute Alcohol Intoxication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <description>Tinnitus</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Diarrhoea</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Gastroenteritis</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Upper respiratory tract infection</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <description>Triglycerides increased</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Back Pain</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Drowsiness</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <description>Sinus Congestion</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Autifony Therapeutics Ltd</organization>
      <phone>+44 1438 906860</phone>
      <email>info@autifony.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

